1. AB0267 Treatment paradigms in real-world practice: biologic agent use prior to and after discontinuation of abatacept in the action study. (15th June 2017) Authors: Alten, R; Lorenz, H-M; Mariette, X; Nüßlein, H; Galeazzi, M; Navarro, F; Chartier, M; Elbez, Y; Rauch, C; Bars, M Le Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 1141 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0412 Less than 5% of real-life patients who switch from iv to sc abatacept in real-world clinical practice subsequently switch back to the iv formulation. (15th June 2017) Authors: Alten, R; Lorenz, H-M; Mariette, X; Nüßlein, H; Galeazzi, M; Navarro, F; Chartier, M; Heitzmann, J; Rauch, C; Bars, M Le Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 1193 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FRI0245 Abatacept retention rates and prognostic factors of retention in patients with rheumatoid arthritis: 2-year results from the real-world action study. (15th June 2017) Authors: Alten, R; Lorenz, H-M; Mariette, X; Nüßlein, H; Galeazzi, M; Navarro, F; Chartier, M; Elbez, Y; Rauch, C; Bars, M Le Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 577 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗